Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 16/20 | 0.65 |
| ▸ | P2RY6 | Q15077 | 11/20 | 0.62 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.61 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uridine SCHEMBL5875823 | 1.00 | P2RY2 (0.65) | P2RY2P2RY6P2RY4SLC28A1SLC28A2 | |
| Uridine SCHEMBL338288 | 1.00 | P2RY2 (0.65) | P2RY2P2RY6P2RY4SLC28A1SLC28A2 | |
| SCHEMBL5068300 | 0.93 | P2RY2 (0.63) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL2352660 | 0.91 | P2RY2 (0.63) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL2346632 | 0.91 | P2RY2 (0.63) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL622268 | 0.91 | P2RY2 (0.62) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL622267 | 0.91 | P2RY2 (0.62) | P2RY2P2RY6P2RY4P2RY14 | |
| Uridine SCHEMBL28456453 | 0.90 | P2RY2 (0.79) | P2RY2P2RY6P2RY4SLC28A1SLC28A2 | |
| Uridine SCHEMBL28898119 | 0.90 | P2RY2 (0.79) | P2RY2P2RY6P2RY4SLC28A1SLC28A2 | |
| Uridine SCHEMBL29482406 | 0.90 | P2RY2 (0.79) | P2RY2P2RY6P2RY4SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2045257-B1 | PROCESS FOR PRODUCING DI(PYRIMIDINE NUCLEOSIDE 5'-)POLYPHOSPHATE | YAMASA CORP (JP) | 2016-08-17 | — | — | EP | claimed |
| US-7109181-B2 | Joint lubrication with P2Y purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | claimed |
| JP-2005508297-A | — | — | 2005-03-31 | — | — | JP | claimed |
| US-20030027785-A1 | Joint lubrication with P2Y purinergic receptor agonists | INSPIRE PHARMACEUTICALS, INC. | 2003-02-06 | — | — | US | claimed |
| WO-2003000056-A1 | JOINT LUBRICATION WITH P2Y PURINERGIC RECEPTOR AGONISTS | INSPIRE PHARMACEUTICALS, INC. (US) | 2003-01-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027785-A1 | Joint lubrication with P2Y purinergic receptor agonists | P2RY1, P2RY2, P2RY6 | P2RY2 2/4885P2RY6 3/4885P2RY4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.